TScan Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TCRX Nasdaq 2836 www.tscan.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TScan Therapeutics, Inc.

2 Small-Cap Stocks Under $10 to Buy With Big Potential - Jun 24th, 2025 5:30 am
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - May 28th, 2025 5:00 am
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates - May 6th, 2025 6:20 am
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 6th, 2025 5:00 am
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting - Apr 28th, 2025 2:53 pm
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Mar 31st, 2025 5:00 am
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - Mar 27th, 2025 5:00 am
TScan Therapeutics Full Year 2024 Earnings: Misses Expectations - Mar 6th, 2025 3:06 am
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates - Mar 5th, 2025 6:25 am
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Mar 5th, 2025 5:00 am
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference - Feb 27th, 2025 5:00 am
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Feb 18th, 2025 5:00 am
TScan Therapeutics Insider Ups Holding By 18% During Year - Feb 5th, 2025 4:09 am
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks - Jan 10th, 2025 7:35 am
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium - Dec 26th, 2024 5:00 am
With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing - Dec 25th, 2024 3:26 am
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank - Dec 23rd, 2024 5:00 am
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition - Dec 9th, 2024 3:45 pm
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years - Dec 5th, 2024 6:00 am
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy - Dec 2nd, 2024 5:00 am